Why the study?
Does aspirin prevent major cardiovascular events in people with diabetes for primary prevention?
Does aspirin prevent major cardiovascular events in people with diabetes for primary prevention?
Answers are grounded in this paper and cite their sources.
Evidence supporting the efficacy of aspirin for primary prevention of cardiovascular events specifically in diabetic patients is scant and lacks statistical significance in previous meta-analyses.
Until recently, aspirin was recom-mended by most guidelines for theprimary prevention of cardiovascu-lar events in people with diabetes. Rec-ommendations were primarily based on indirect evidence from large trials of pop-ulations at high risk of cardiovascular (CV) events. Evidence supporting the efficacy of aspirin therapy in trials of diabetic subjects only is scant. A previous meta-analysis on the efficacy of antiplatelet therapy in the prevention of major CV events found a clear benefit of aspirin overall, but no statistically significant benefit in the sub-group of people with diabetes. No signif-icant reduction in the risk of major CV events with low dose aspirin compared
No takes yet. Share an insight, caveat, or question.
Nicolucci et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: